View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
November 18, 2021updated 11 Jul 2022 2:17pm

Novartis to continue studying Ilaris in NSCLC despite CANOPY-1 trial failure

In spite of the failure of the Phase III pivotal CANOPY-1 trial, Novartis will keep on studying Ilaris as a treatment for early-stage lung cancer.

By GlobalData Healthcare

On October 25, Novartis published a press release stating that the Phase III pivotal CANOPY-1 trial of Ilaris (canakinumab) in combination with Merck & Co’s programmed cell death protein (PD)-1 inhibitor, Keytruda (pembrolizumab), and platinum-based doublet chemotherapy in patients with previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC) did not meet its co-primary endpoints of overall survival (OS) and progression-free survival (PFS). However, Novartis will continue to examine Ilaris in the treatment of early-stage lung cancer, as top-line results show that clinically meaningful improvements in both endpoints were observed in pre-specified subgroups of patients with inflammatory biomarkers such as high-sensitivity C-reactive protein (hs-CRP).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Novartis’ human anti-interleukin-1β (IL-1β) monoclonal antibody, Ilaris, was previously studied in the prevention of recurrent cardiovascular events in post-myocardial infarction patients with elevated hs-CRP, who were at risk of developing inflammatory cancers, in the Phase III, pivotal CANTOS trial. Significantly lower death rates from lung cancer were observed among subjects in this trial after IL-1β inhibition, hence Ilaris was studied in both the neoadjuvant and adjuvant settings for the treatment of different stages of NSCLC in the CANOPY programme (three randomised Phase III trials and one Phase II trial). In March of this year, Novartis endured its first setback after the Phase III CANOPY-2 trial of Ilaris, in combination with docetaxel chemotherapy in patients with locally advanced or metastatic NSCLC who progressed on platinum-based chemotherapy and PD-1 inhibitor, failed to meet its primary endpoint.

Although the CANOPY-A trial is currently recruiting patients in the adjuvant setting, the recent approval by the FDA of Roche’s Tecentriq (atezolizumab) in this setting pushes Ilaris further down the pecking order and realistically leaves the Phase II CANOPY-N trial of Ilaris in the neoadjuvant setting as the most likely pathway for Ilaris to penetrate the NSCLC market.

Key opinion leaders (KOLs) support the rationale of combining an anti-angiogenesis agent such as Ilaris with immunotherapy to potentiate efficacy and overcome chemoresistance. Given the immune checkpoint inhibitor (ICI)-dominated nature of the NSCLC space in the eight major markets (8MM) (the US, France, Germany, Spain, Italy, the UK, Japan and China), some of the most promising pipeline drugs are those that combine with already marketed ICIs such as Keytruda. Ilaris and Eisai’s Lenvima (lenvatinib mesylate) are pipeline agents that are both likely to be marketed in combination with Keytruda in the US by 2024. According to GlobalData’s patient-based NSCLC forecast, Ilaris’ and Lenvima’s sales in the US in the first-line setting are expected to reach $103m and $63m, respectively, by 2029 if approved. If the two trials are able to demonstrate efficacy by adding synergistic or additive benefits compared to immune checkpoint blockade, these combinations will become a viable therapeutic strategy in the neoadjuvant setting.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Related Report
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena